

Present Value of Toviaz U.S. Sales

Year	U.S. Sales		Inflation Adjustment		Present Value Factor		Present Value of U.S. Sales			
	[A]		1998	2008	1998	2008	1998	2008		
	\$		[B]	[C]	[D]	[E]	[F]	[G]		
2009	\$	10.8	0.760	1.004	0.313	0.890	\$	2.6	\$	9.6
2010	\$	54.7	0.748	0.987	0.283	0.805	\$	11.6	\$	43.5
2011	\$	94.0	0.725	0.957	0.256	0.729	\$	17.5	\$	65.6
2012	\$	115.2	0.710	0.938	0.232	0.659	\$	19.0	\$	71.2
2013	\$	120.0	0.700	0.924	0.210	0.597	\$	17.6	\$	66.2
2014	\$	133.0	0.689	0.909	0.190	0.540	\$	17.4	\$	65.3
Total	\$	527.7	n/a	n/a	n/a	n/a	\$	85.6	\$	321.5

Notes and sources:

Monetary values are in millions of \$U.S.

[A] Nominal U.S. sales figures are from Exhibit 1036.

[B] to [C] = 1 / (CPI for specified year (row) / CPI for specified year (column)) from Exhibit 1049.

[D] to [E] Calculated from month and day of Toviaz approval (October 31) for 2008 and patent priority (May 12) for 1998.

The discount rate used is 10.5% based on:

Grabowski, Henry and Ronald Hansen, "Briefing Cost of Developing a New Drug," Tufts Center for the Study of Drug Development, 11/18/2014, at 20.

[F] = [A] x [B] x [D].

[G] = [A] x [C] x [E].